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Molecular mechanismAdenosine is a ubiquitous signaling molecule whose physiological functions are mediated by its interaction
with four G-protein-coupled receptor subtypes, termed A1, A2A, A2B and A3. As a result of increased metabolic
rates, this nucleoside is released from a variety of cells throughout the body in concentrations that can have a
profound impact on vasculature and immunoescape. However, as high concentrations of adenosine have been
reported in cancer tissues, it also appears to be implicated in the growth of tumors. Thus, full characterisation
of the role of adenosine in tumor development, by addressing the question of whether adenosine receptors
are present in cancer tissues, and, if so, which receptor subtype mediates its effects in cancer growth, is a vital
research goal. To this end, this review focuses on the most relevant aspects of adenosine receptor subtype
activation in tumors reported so far. Although all adenosine receptors now have an increasing number of
recognised biological roles in tumors, it seems that the A2A and A3 subtypes are the most promising as regards
drug development. In particular, activation of A2A receptors leads to immunosuppressive effects, which
decreases anti-tumoral immunity and thereby encourages tumor growth. Due to this behavior, the addition of
A2A antagonists to cancer immunotherapeutic protocols has been suggested as a way of enhancing tumor
immunotherapy. Interestingly, the safety of such compounds has already been demonstrated in trials
employing A2A antagonists in the treatment of Parkinson's disease. As for A3 receptors, the effectiveness of
their agonists in several animal tumor models has led to the introduction of these molecules into a
programme of pre-clinical and clinical trials. Paradoxically, A3 receptor antagonists also appear to be
promising candidates in human cancer treatment of regimes. Clearly, research in this still ﬁeld is still in its
infancy, with several important and challenging issues remaining to be addressed, although purine scientists
do seem to be getting closer to their goal: the incorporation of adenosine ligands into drugs with the ability to
save lives and improve human health. This article is part of a Special Issue entitled: “Adenosine Receptors”.osine Receptors”.
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The purine nucleoside adenosine is consensually identiﬁed as a
major local regulator of tissue function especially when energy supply
fails tomeet cellular energydemand.Due to its ability to equalize energy
intake to metabolic demand, in the 1980s it earned the reputation of a
1401S. Gessi et al. / Biochimica et Biophysica Acta 1808 (2011) 1400–1412“retaliatory metabolite” [1]. Adenosine is omnipresent, released from
almost all cells, and generated in the extracellular space by breakdown
of ATP through a series of ectoenzymes, including apyrase (CD39) and
5′-nucleotidase (CD73) [2]. The latter dephosphorylates extracellular
AMP to adenosine, regulating the limiting step for its formation.
Extracellularly, adenosine concentration is kept in equilibrium by
reuptake mechanisms operated through the action of speciﬁc transpor-
ters. Then inside the cell it is phosphorylated to AMP by adenosine
kinase or degraded to inosine by adenosine deaminase (ADA).
Intracellularly, adenosine formation is dependent upon the hydrolysis
of AMP by an intracellular 5-nucleotidase or hydrolysis of S-adenosyl-
homocysteine. It is estimated that the levels of adenosine in the
interstitial ﬂuid are in the range 20–200 nM [3]. Adenosine concentra-
tions increase under metabolically unfavorable conditions. Tissue
hypoxia, for example, leads to an enhanced breakdown of ATP and an
increased generation of adenosine. In addition to this route, the release
of adenosine might be potentiated by hypoxia-dependent inhibition of
the salvage enzyme adenosine kinase which rephosphorylates the
nucleoside toAMP [4]. As adenosine is unstable and itshalf-life is limited
by deamination or cellular reuptake, hypoxia-induced increase typically
affects only local adenosine receptor (AR) signaling. Adenosine effects
are widespread and pleiotropic. The cellular response to this autacoid
strictly depends on the expression of the different AR subtypes, which
can be co-expressed by the same cell and serve as active modulators in
signal transduction. ARs have been actively studied as potential
therapeutic targets in several disorders such as Parkinson's disease,
schizophrenia, analgesia, ischemia, and cancer. Indeed, an overview of
the recent advances reported regarding the implication of ARs in the
latter disease is the focus of this review.
2. Adenosine receptors
Adenosine mediates its effects through activation of a family of four
G-protein-coupled ARs, named A1, A2A, A2B, and A3. These receptors
differ in their afﬁnity for adenosine, in the type of G proteins that they
recruit, and ﬁnally in the downstream signaling pathways that are
activated in the target cells. A1, A2A andA3ARsdisplayhigh afﬁnitywhile
A2B displays low afﬁnity for adenosine [5,6]. These receptors are seven
transmembrane glycoproteins coupled with G proteins and are widely
distributed throughout the body. A1AR stimulation through interaction
with different members of pertussis toxin-sensitive family of G proteins
(Gi1, Gi2, Gi3 and G0) may modulate adenylyl cyclase (AC), calcium
channels, potassium channels and phospholipase C (PLC). The A2AAR
through coupling with Gs/Golf proteins activates AC activity and its
stimulation increases the intracellular cyclic adenosinemonophosphate
(cAMP) concentration. TheA2BAR, through couplingwithGs/Gqprotein,
increases activity of AC and stimulates PLC. Finally, the A3AR through
interaction with Gi and Gq proteins inhibits AC and stimulates PLC,
respectively [7]. Furthermore, depending on the cell type studied, ARs
may also signal through the activation of mitogen-activated protein
kinase (MAPK) signaling pathway. The MAPK pathways are critically
important in the regulation of cell proliferation and differentiation [8].
There are numerous extracellular signals feeding into these cascades,
including input via GPCRs [9]. All four subtypes of ARs have been shown
to mediate extracellular signal-regulated kinase (ERK) 1/2 phosphor-
ylation in transfected Chinese hamster ovary (CHO) cells [10,11]. MAPK
signaling and hence cell proliferation might be amenable to manipula-
tion through speciﬁc ARs in tumor cells. Recently, different classes of
proteins have been recognized as interacting with ARs. These proteins
include serine – threonine or tyrosine protein kinases, β-arrestins and
scaffolding proteins within others [5].
3. Adenosine receptors (ARs) and cancer
One of the ﬁrst evidence concerning the involvement of adenosine
in cancer comes from the studies in immune cells. It is known that theability of immune cells to ﬁght tumor cells is fundamental for
successful host defence against cancer. Adenosine, whose concentra-
tion increases within hypoxic regions of solid tumors, has been
recognized able to interfere with the recognition of tumor cells by
cytolytic effector cells of the immune system [12,13]. Adoptive
immunotherapy with lymphokine-activated killer (LAK) cells has
shown some promise in the treatment of certain cancers that are
unresponsive to conventional treatment approaches. However, colon
adenocarcinomas tend to respond poorly to LAK therapy, possibly as a
result of tumor-induced immunosuppression. It has been demon-
strated that colon adenocarcinoma cells inhibited anti-CD3-activated
killer cell induction through the production of a tumor-associated
soluble factor that was distinct from transforming growth factor-beta
(TGF-β) or prostaglandins [14]. Therefore, adenosine was indicated as
a possible inhibitor of killer T-cell activation in the microenvironment
of solid tumors [15,16]. Indeed, evaluating the adhesion of murine
spleen-derived anti-CD3-activated killer (AK) lymphocytes to synge-
neic MCA-38 colon adenocarcinoma cells, it was found that adenosine
reduced adhesion by up to 60% [17]. The inhibitory effect of adenosine
was exerted on AK cells and not on the MCA-38 targets and the
agonist potency proﬁle indicated that the A3AR subtype might be
responsible for the inhibition of adhesion. It has been suggested that
this mechanism of immunosuppression, secondary to tissue hypoxia,
may be important in the resistance of colorectal and other solid
cancers to immunotherapy. In addition it has been demonstrated that
adenosine plays a strong inhibitory role on the induction of mouse
cytotoxic T-cells [18]. The inhibitory effect of adenosine on AK-T cell
proliferation was also blocked by an A3AR antagonist suggesting that
adenosine stimulates A3ARs to prevent AK-T cell induction. Tumor-
associated adenosine may act through the same mechanism to impair
the development of tumor-reactive T cells in cancer patients.
Therefore the suppression of T-killer cell function suggests that
adenosine may behave as a local immunosuppressant within the
microenvironment of solid tumors. Subsequently, it was reported that
adenosine partially inhibits the interaction of T lymphocytes with
tumor cells by blocking the function of integrinα4β7 that is the major
cell adhesionmolecule involved in the adhesion of T cells to syngeneic
MCA-38 adenocarcinoma cells [19]. The effect of adenosine on the
expression of costimulatory molecules by T cells in resting and
activated conditions has been investigated. One of themost important
costimulatory molecules present on the T cells' surface are CD2 and
CD28 acting in concert to achieve optimal costimulation of T
lymphocytes during interaction with antigen presenting cells. It has
been demonstrated that adenosine interfered with activation-induced
expression of the costimulatorymolecules CD2 and CD28 in away IL-2
dependent, but not involving the accumulation of intracellular cAMP,
possibly by activating the A3 subtype [20]. However, other data
obtained from studies using AR knock-out (KO) mice examined the
capability of adenosine and its analogues to inhibit the ability of LAK
cells to defeat tumor cells. This work demonstrated that adenosine
and adenosine A2A ligands suppress the cytotoxicity of LAK cells in
parallel with their ability to increase cAMP levels. Studies with LAK
cells generated from A1 and A3AR KO mice indicated the lack of any
involvement of these adenosine subtypes in the inhibitory effect
exerted by adenosine, whereas LAK cells obtained from A2AR KOmice
were resistant to the inhibitory effect of the nucleoside. Only very
high concentrations of the non-selective agonists 5-N-ethylcarbox-
amide adenosine (NECA) or 2-chloroadenosine (CADO) produced
mild inhibition of LAK cytotoxicity that were possibly induced
through A2B activation, suggesting the predominant role of the A2A
subtype in inhibition of LAK cell toxicity [21]. Therefore, the use of A2A
antagonists has been suggested to increase the efﬁcacy of immu-
notherapy [22].
In order to shed light on the role of adenosine in cancer, we report
here the plethora of data performed in “in vitro” and in “in vivo” studies
for each AR subtype.
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In spite of the various studies investigating the role of A1AR in
tumor development its role is not well characterized. A1ARs have been
associated to carcinogenesis in previous investigations where the
expression of this receptor has been demonstrated in colorectal
adenocarcinomas and peritoneal colon tissues [23]. A1ARs have been
detected also in the human leukemia Jurkat and human melanoma
A375 cell lines [24,25]. Despite this association, in human LoVo
metastatic cell line A1 agonists inhibited proliferation [26] and similar
antiproliferative effects were reported for TM4, a Sertoli-like cell line
[27]. Proliferation in human tumor cells (leukemia MOLT-4, breast
tumors T47D, HS578T andMCF-7)was inhibited by A1 stimulation. On
the other hand, the A1AR, endogenously expressed in melanoma cell
line, has been demonstrated to increase the chemotaxis of tumor cells.
Otherwise, unresponsive CHO cells transfected with the adenosine
A1AR cDNA (CHO-hA1) acquired the direct, pertussis toxin-sensitive,
chemotactic response to adenosine, and this responsewas inhibited by
AR antagonists [28]. These ﬁndings demonstrate that adenosine and
adenine nucleotides are capable of stimulating chemotaxis of tumor
cells probably through the A1AR subtype. Consistent with a protu-
moral effect of the A1AR, it has been reported that human primary
breast tumor tissues express higher levels of A1ARs than in matched
normal breast tissues. A1ARs have been detected also in MDA-MB-468
human tumor cell lines where depletion of A1ARs attenuates both cell
growth and cell proliferation. Cell cycle analysis indicated that
depletion of A1ARs by siRNA impairs G1 checkpoint, leading tomarked
accumulation of cells in G2/M phase, in agreement with the inhibitory
effect on cell proliferation. Further supporting this ﬁnding, synchro-
nization studies of HeLa cells in various cell cycle phases suggest that
A1AR expression is suppressed in G2/M cells and depletion of A1AR
expression by siRNA produced differential expression of several key
cell cycle regulators, i.e., accumulation of the cyclin-dependent kinase
inhibitor p27 with concomitant reduction of CDK4 and cyclin E
proteins. In addition to the impact on cell cycle progression, depletion
of A1ARs by siRNA results in substantial cell death and apoptosis.
Together theseﬁndings suggest that theA1ARmay contribute to tumor
cell growth and survival in breast tumor cells [29].
The density of A1ARs in F98 glioma-bearing rats has been found to be
increased in zones surrounding experimental tumors. Immunostaining
identiﬁed activated astrocytes as the main origin of peritumoral A1Fig. 1. Role of A1AR in cancer development. Schematic representation of the principalupregulation. These results have been conﬁrmed in a pilot studywith 8-
cyclopentyl-3-(3-18F-ﬂuoropropyl)-1-propylxanthine (18F-CPFPX)
using PET on a patient with recurrent glioblastoma multiforme [30].
The distribution of A1 in rat brain tumors and in rat C6 glioma cells has
been conﬁrmed in different studies [31,32]. In particular, it has been
reported that adenosine-mediated inhibition of glioblastoma growth is
dependent on activation of A1 in microglial cells [33]. This implies that
adenosine, acting via A1AR, impairs glioblastoma growth.
Accordingly, it has been reported that in rat astrocytoma cells
extracellular adenosine appears to activate caspase-9 followed by the
effector caspase-3, at least via two independent pathways linked to
A1AR-mediated AC inhibition and adenosine uptake into cells. This
study represents a new pathway for caspase activation relevant to
diverse adenosine signals in cell death [34].
More recently, it has been shown that extracellular adenosine-
induced apoptosis of CW2 human colonic cancer cells by activating
caspase −3, −8 and −9, and the effect was inhibited by an A1AR
antagonist. For mice inoculated with CW2 cells, intraperitoneal
injectionwith adenosine reduced tumor growth by inducing apoptosis
mediated via A1ARs [35]. The results from the studies described above
suggest that the A1AR plays an antitumorigenic role in the develop-
ment of glioblastomas. Further research into the mechanisms of how
the pathways of A1AR signaling modulate glioblastoma development
may ultimately lead to treatments to reduce the progression of this
disease.
The pro- and anti-tumoral effects induced by A1AR activation are
summarized in Fig. 1.
5. Role of A2A adenosine receptors (A2AARs) in cancer
A2AARs have been found on cell membranes of different human
tumor cells: SH-SY5Y neuroblastoma, NG108-15 neuroblastoma x
glioma hybrid, U937 monocytic lymphoma, Jurkat T-cell leukemia,
A375 melanoma, A431 epidermoid cells, colon carcinoma HT29 and
DLD-1 cells,U87MGhumanglioblastomacells, andhumanbreast cancer
MCF-7 cells [24,25,36–43].
Treatment with an adenosine A2A agonist results in a reduction in
neuronal apoptosis and a decrease in spinal cord reperfusion inﬂam-
matory stress during rabbit spinal cord reperfusion [44]. It is possible to
achieve infarct reduction with adenosine, inhibiting apoptosis. The
inhibition of apoptosis by adenosine at reperfusion involves thepathways activated by A1AR in the modulation of pro- and anti-tumoral effects.
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neutrophil accumulation, primarily mediated by an A2AAR [45].
Despite this anti-apoptotic role on normal tissue, activation of
adenosine A2AAR has been shown to promote cell death of human A375
melanoma cells [46]. Accordingly, it has been reported that extracellular
adenosine induces apoptosis by activating caspase-9 and caspase-3 in
association with mitochondrial damage via A2AARs in Caco-2 human
colonic cancer cells [47].
Furthermore, adenosine promotes wound healing and mediates
angiogenesis in response to tissue injury via occupancy of A2AARs [48].
Angiogenesis is the requisite not only for continued tumor growth, but
also for metastasis. Without access to the vasculature, the tumor cells
cannot metastasize. Hence, angiogenesis is a necessary biologic feature
of malignancy. Several studies have revealed a correlation between the
extent of angiogenesis (microvessel density) and the probability of
metastases in melanomas and cancers of the breast, lung, colon, and
prostate. In some of these cancers (breast, prostate) vessel density has
proven to be a signiﬁcant prognostic indicator. A2AAR occupancy
promotes endothelial cell proliferation, migration and synthesis of
message for the important angiogenic growth factor such as vascular
endothelial growth factor (VEGF) [48–51]. These data suggest that
A2AARs are involved in promotion of angiogenesis. Thus, it has been
hypothesized that A2AAR antagonists may exert anti-tumoral effects by
impairing solid tumor growth and spreading.
On the other hand, in the vasculature, A2AARs have been detected on
both the smooth muscle and endothelium, where they are associated
with vasodilatation [52]. Agonists of A2AARs may be used to improve
vasodilatation of intratumoral blood vessels enhancing delivery of
anticancer drugs into the tumor tissue. This may be particularly
important for malignant brain tumors where the limited effectiveness
of chemotherapy has been related to insufﬁcient drug delivery into the
tumor parenchyma. The results presented above provide further
evidence for an active role of A2AARs in tumor growth.
A2AARs have been shown to increase erythropoietin (EPO) produc-
tion in hepatocellular carcinoma (Hep3B) cells in culture and in vivo in
rats and mice under normoxic and hypoxic conditions [53,54]. It has
been reported that renal cell carcinoma, hepatocellular carcinoma and
cerebellar hemangioblastoma are EPO-secreting tumors. This inappro-
priate (pathologic) secretion of EPO may cause secondary polycythe-
nias, an increase in red cell mass. It has been demonstrated that
adenosine activates EPO production through the A2AARs, suggesting
that the adenosinergic system may allow gaining a deeper insight into
the pathophysiology of this disorder. In particular, A2A antagonists may
be a reasonable therapeutic target for stopping increased levels of EPO.
It is well known that adenosine is involved in the inhibition of
immune function [55,56]. In particular A2AARs on T-cell surface may
play an immunosuppressive role in large solid tumors where hypoxic
conditions are known to cause accumulation of extracellular adenosine,
which, in turn, could inhibit incoming antitumor cytotoxic T lympho-
cytes from destroying the tumor [57]. The immunosuppressive role and
the ability to protect against ischemia suggest that A2AAR activation
improves hypoxic tumor cell survival and immuno escaping. A role for
the A2AAR in protecting host tissue from destruction by overexuberant
immune responses has been established. Considering that the tumor
microenvironment contains relatively high levels of extracellular
adenosine, data support the hypothesis that tumor-derived adenosine
is one mechanism by which tumors evade immune destruction
[12,15,58]. In particular, the important work by Ohta and Sitkovsky
[59] established for the ﬁrst time the nonredundant role of the A2AAR in
mediating adenosine-induced anti-inﬂammatory responses in A2AAR
KOmice [59]. These KOmice are unable to control inﬂammation, which
leads to extensive, often fatal, tissue destruction. For example, when
immune-mediated liver inﬂammationwas induced inmice by injecting
Con A, the A2AAR KO mice died because of massive immune-mediated
liver destruction. These observations led to a model whereby tissue
damage resulting from inﬂammation leads to the release of extracellularadenosine, which then acts to reduce the inﬂammatory response by
acting on bone marrow-derived immune cells. Indeed, A2AAR signaling
on immune cells such as macrophages, T cells and dendritic cells has
been shown to limit effector cell function [60–66]. The existence of this
negative feedback loop has led Sitkovsky to propose that, from an
immunologic prospective, adenosine should be viewed as ametabokine
that acts as an inhibitory second signal [67,68].
Furthermore adenosine acting via the A2AAR has the ability to
inﬂuence inﬂammation by inhibiting proinﬂammatory cytokine secre-
tion, C2activation,macrophage-mediatedphagocytosis, and superoxide
production [69]. Likewise, A2AAR activation has profound effects on the
adaptive immune response. A2AAR activation inhibits both CD4+ and
CD8+ T-cell function [60,63,64,70,71]. Interestingly, A2AAR activation
on T cells seems to selectively inhibit proinﬂammatory cytokine
expression while sparing anti-inﬂammatory cytokine expression [64].
Along these lines, it has been shown that adenosine acting via the
A2AAR might partially mediate the suppressive function of regulatory T
(Treg) cells, crucial formaintaining tolerance to self and thus preventing
autoimmune diseases and allograft rejections, by engaging the A2AARs
on the suppressed cells [72]. It was found that the ectoenzymes CD39
and CD73 appear to be more speciﬁc markers for Treg cells than CD25
[72]. In particular, TCR-activated Treg cells express A2AAR, A2BAR and
hypoxia-inducible factor (HIF-1) which leads to the enhanced tran-
scription of genes that have hypoxia and/or cAMP-response elements
(HRE and CRE, respectively). These genes, e.g. IL-10, TGF-β, Galectin-1,
and Foxp3 have been implicated in Treg cell function and development
[68]. Therefore, A2AR stimulation not only inhibits the generation of
adaptive effector T cells but alsopromotes the inductionof adaptiveTreg
cells. A2AAR signaling during an initial antigen encounter can induce a
state of anergy in primary T cells such that they are hyporesponsive on
rechallenge. T cells initially stimulated in thepresence of anA2AR agonist
fail to proliferate and produce IL-2 and interferon (IFN)-γ when
rechallenged in the absence of A2AR stimulation. Likewise, in an in
vivo model of autoimmunity, tissue-derived adenosine promotes
anergy and abrogates tissue destruction. Indeed, A2AR stimulation
inhibits IL-6 expression while enhancing the production of TGF-β.
Accordingly, treatingmice with A2AR agonists not only inhibits Th1 and
Th17 effector cell generation but also promotes the generation of Treg
cells [71]. The generation and accumulation of immunosuppressive
adenosine by human Treg cells has been conﬁrmed in recent studies
[73,74]. Importantly, A2AAR KO mice exhibit enhanced antitumor
immune responses by CD8+ T cells, as well as a dramatic reduction in
thegrowthof experimental tumors in comparison towild-type controls.
A2AAR signaling has also been implicated in adenosine-mediated
inhibition of cytokine production and cytotoxic activity by activated
natural killer (NK) cells [75].
Promising strategies to enhance immunosurveillance of cancer will
come by the development of A2AAR antagonists that may interfere with
the ability of extracellular adenosine to induce a local immunosuppres-
sion in tumors. Indeed, it has been recently reported that adenosine-
resistant effector T cells were successfully obtained by exposure of
activated T cells to NECA. These in vitro studies form the basis for future
attempts to produceantitumor T cells that aremore effective inadoptive
immunotherapy [76].
Finally, the A2A agonist stimulates the proliferation of MCF-7 cells
and interferes with the ethanol-induced activation of estrogen receptor
(ER) signal transduction, opening a new perspective for the therapy of
estrogen-dependent breast cancer [43].
The pro- and anti-tumoral effects induced by A2AAR activation are
summarized in Fig. 2.6. Role of A2B adenosine receptors (A2BARs) in cancer
The distribution of the gene transcript indicates that the A2BAR is
expressed in many tissues and cell types. However, it is clear that the
Fig. 2. Role of A2AAR in cancer development. Schematic representation of the principal pathways activated by A2AAR in the modulation of pro- and anti-tumoral effects.
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under pathophysiological rather than physiological conditions [3,5].
Extracellular adenosine induces apoptosis of human arterial smooth
muscle cells via A2BAR, involving a cAMP dependent pathway [77].
Adenosine regulates macrophage proliferation by interacting with the
A2BAR and subsequently inducing the production of cAMP [78].
A2BARs are predominantly expressed in human microvascular cells
and are believed to modulate expression of angiogenic factors [79]. In
particular, adenosine activates the A2BAR in human retinal endothelial
cells (HRECs), which may lead to neovascularization by a mechanism
involving increased angiogenic growth factor expression [80]. In regard
to this, A2BAR inhibition may offer a way to inhibit retinal angiogenesis
and provide a novel therapeutic approach to the treatment of diseases
associated with aberrant neovascularization, such as diabetic and
prematurity retinopathy [81]. In light of this, antagonists for A2BARs
appear to be useful in vivo to impair neovasculogenesis associated to
tumor development and growth.
Adenosine causes growth inhibition of cardiac ﬁbroblasts, aortic and
vascular smoothmuscle cells by the activation of A2BARs [82–86], while
it increases the proliferation of rat arterial endothelial cells via A2BARs
[87]. It is interesting to note that, in contrast to smooth muscle cells,
A2BARs induce growth of endothelial cells [80]. In view of the fact that
A2BAR stimulation improves cell proliferation of the peripheral micro-
vessels, we can hypothesize that, as a consequence of this ability to
promote the endothelial cell proliferation, A2B may contribute to tumor
growth and spreading by inducing neovascularization in the area
surrounding the tumor masses. The A2BAR also seems to be responsible
for the release of a certain subset of cytokines [88,89]. A2BARs are
expressed in human microvascular endothelial cells, where they play a
role in the regulation of the expression of angiogenic factors like VEGF,
interleukin-8 (IL-8), and basic ﬁbroblast growth factor (bFGF) [79].
Moreover, in human mast cells (HMC-1) derived from a highly
malignant, undifferentiated human mastocytoma cancer, activation of
A2BARs induces the release of IL-8 and VEGF, and the activation of A3ARs
induces angiopoietin 2 expression [88]. However, capillary formation
induced by HMC-1 media was maximal when both HMC-1 A2BARs and
A3ARs were activated. Activation of A2BARs alone was less effective,
suggesting cooperation between A2BARs and A3ARs on HMC-1 cells to
produce angiogenesis. Furthermore, in HT29 human colon cancer cells
adenosine increases IL-8 expression via stimulation of A2BARs,while thestimulation of A3AR caused an increase in VEGF [89]. In the glioblastoma
cell lineU87MG, a similarA2BAR-mediated increaseof IL-8wasobserved
[90]. In addition, it was shown that hypoxia caused an upregulation of
A2BARs in these tumor cells. As these ﬁndings point to a crucial role for
A2BARs in mediating the effects of adenosine on angiogenesis, blockade
of A2BARs may limit tumor growth by limiting the oxygen supply.
Data demonstrating A2BAR-mediatedmodulation of neovasculariza-
tion may have interesting implications in the identiﬁcation of novel
drugs that, blockingA2BARs,maybeutilized to induceprotection against
tumors.
A2BARs are also involved in themRNA and protein increase of IL-6 in
human astroglioma cells [91].
It has been reported that the ER-positiveMCF-7 cells appeared to be
devoid of any detectable amount of ARs, whereas the ER-negative
MDA-MB-231 cells express veryhigh levels ofA2BARs. ThisAR subtype is
responsible for the unusual inhibitory signal on ERK 1/2 phosphoryla-
tion. Moreover, antagonists like 1,3-dipropyl-8-cyclopentylxanthine
(DPCPX) block this response, conﬁrming the identity of the AR subtype
as the A2BAR mediating the inhibition of ERK 1/2 phosphorylation [92].
The exact pathway leading to A2BAR-mediated inhibition is not fully
understood at this point. Both the Ca2+ signal detected following A2BAR
stimulation in MDA-MB-231 cells [92] and PLC activation are sufﬁcient,
as their blockade abolishes the inhibition of ERK 1/2 phosphorylation. A
few studies describe such an uncommon antiproliferative GPCR-
mediated signal in glomerular mesangial cells [93] and in vascular
smoothmuscle cells [85]. The high expression levels of A2BARs in an ER-
negative breast cancer cell line together with a link to an antiprolifera-
tive signaling pathway make this AR subtype a potentially interesting
target for tumor treatment, perhaps in combination with drugs
interfering with downstream effectors in MAPK signaling pathways
[94]. There is an increasing amount of data conﬁrming that A2BARs play
an important role inmediating the effects of adenosineon tumor growth
and progression. The effects which are most interesting for a potential
anticancer treatment based on A2BARs as a target are inhibition of
angiogenesis and inhibitionof ERK1/2phosphorylation. Thedilemma is,
however, that inhibition of angiogenesis requires the use of A2BAR
antagonists, whereas inhibition of growth signaling via the MAPK
pathwaymight beachieved through treatmentwithA2BARagonists. The
relative importance of these effects needs to be investigated using in
vivo models before therapeutic suggestions can arise. It may eventually
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for treatment in combinationwith other therapeuticmeasures if used at
different stages of the disease.
A2BARs KO mice exhibited signiﬁcantly attenuated tumor growth
and longer survival times after inoculation with Lewis lung carcinoma
compared to wild-type (WT) controls. Lewis lung carcinoma tumors in
A2BARs KOmice contained signiﬁcantly lower levels of VEGF compared
to tumors growing in WT animals. Thus, these data suggest that tumor
cells promote their growthbyexploitingA2BAR-dependent regulation of
VEGF in host immune cells [95].
It has been demonstrated that the DNA-damaging agents etoposide
and doxorubicin can increase IL-8 expression in human melanoma
cancer cells. In particular, it has been shown that A2BAR blockade can
impair IL-8 production in melanoma cells treated with etoposide and
doxorubicin. This understanding may present the possibility of using
A2BAR antagonists to reduce chemotherapy-induced inﬂammatory
cytokine production [96].
The pro- and anti-tumoral effects induced by A2BAR activation are
summarized in Fig. 3.
7. Role of A3 adenosine receptors (A3ARs) in cancer
A3ARs are present in different types of tumor cells, such as HL60 and
K562 human leukemia [97,98], Jurkat lymphoma [24], U937monocytic-
macrophagic human cell lines [99,100], Nb2 rat lymphoma [101], A375
humanmelanoma [25], PGT-betamouse pineal gland tumor cells [102],
human glioblastoma [42,103], and human prostatic cells [104]. It is well
established that A3 expression is highly sustained in tumor cells
[24,25,98,102]. In more recent studies, a comparison between A3AR
expression in tumor vs adjacent and relevant normal tissues supported
the assumption that the receptor is upregulated in colorectal cancer.
Furthermore, there is substantial evidence showing that A3AR expres-
sion level is directly correlated to disease severity [105]. The receptor
density values of the A3AR in colon carcinoma tissues from 73 patients
revealed an increased density of this subtype in comparison to adjacent,
remote, and healthy colon mucosa [105] (Fig. 4). Interestingly, large
adenomas showed increased binding vs small adenomas, which had
afﬁnity and density values thatwere very similar to those of themucosa
of healthy subjects. An additional result of this study was that receptor
afﬁnity anddensity values (KdandBmax, respectively)were reﬂected in
the peripheral blood lymphocytes and neutrophils of the patients withFig. 3. Role of A2BAR in cancer development. Schematic representation of the principalcolon carcinoma. Upon tumor resection, the A3AR binding values
returned to that of the healthy subjects, suggesting that the receptor
may represent a biological marker [105]. Similar data showing higher
A3AR protein and mRNA expression levels in human melanoma, colon,
breast, small-cell lung, and pancreatic carcinoma vs adjacent non-
neoplastic tissue or normal tissue were reported, suggesting that the
A3AR upregulation is a phenomenon common to differentmalignancies
[106]. Further analysis revealed that the lymphnode metastasis
expressed even more A3AR mRNA levels than the primary tumors,
supporting the notion that A3AR levels may reﬂect the status of tumor
progression [106]. Moreover, computational analysis using different
database sources supported the biological analysis that A3AR is over-
expressed in tumor tissues [106]. In a comparative study, it has been
shown that primary thyroid cancer tissues express high levels of A3ARs,
as determined by immunohistochemistry analysis, whereas normal
thyroid tissue samples do not express A3ARs [107]. Accordingly, it has
been reported that, except for the aorta and heart, during normal
embryo development no expression of A3ARs was found [108].
In a further study, it has been shown that A3AR mRNA expression is
upregulated inhepatocellular carcinoma (HCC) tissues in comparison to
adjacent normal tissues [109]. Remarkably, upregulation of A3AR was
also noted in peripheral bloodmononuclear cells (PBMCs) derived from
the HCC patients compared to healthy subjects. These results further
show that A3AR in PBMCs reﬂects receptor status in the remote tumor
tissue [109].
Taken together, the ﬁndings described above that show A3AR over
expression in different tumor cell types provide the rationale that this
receptor may be utilized as a speciﬁc target to treat cancer [110].
As for the role of A3AR in tumors, it has been reported that it is
involved in the regulation of the cell cycle and both pro and anti-
apoptotic effects have been reported depending on the level of
receptor activation [41,99,111–114]. Starting from the observation
that muscle tissues are resistant to tumor metastases, it was reported
that one of the active components of muscle cell conditioned medium
was adenosine, that exerted a differential effect on tumor and normal
cell growth [115]. This inhibition was removed when the A3AR was
blocked, whilst it was mimicked following A3AR agonist stimulation.
The mechanismwas found to involve inhibition of telomerase activity
and arrest in the G0/G1 phase of the cell cycle, leading to a cytostatic
effect in Nb2-11C lymphoma cells [101]. In addition it was demon-
strated that A3AR inhibited tumor growth by regulation of the WNTpathways activated by A2BAR in the modulation of pro- and anti-tumoral effects.
Fig. 4. The A3AR as tumoral marker. Expression of A3ARs in colon tumor and surrounding peritumoral normal mucosa at a distance of about 2 and 10 cm from the tumor. Kd and Bmax
are afﬁnity binding constant of [3H]MRE 3008 F20 to A3ARs and receptor density of A3ARs, respectively, as reported in [105].
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tumorigenesis, mediates cell cycle progression and cell proliferation.
A key modulator of this pathway is represented by glycogen synthase
kinase (GSK)-3β that is crucial for β-catenin phosphorylation. β-
catenin induces the transcription of genes fundamental for cell cycle
progression such as c-myc and cyclin D1. Upon exposure of tumor cells
to theA3 agonist, a decrease in the protein expression level of A3AR and
the downstream effectors protein kinase A (PKA) and protein kinase B
(PKB/Akt) was observed. Consequently, the GSK-3β protein level
increased, resulting in the destabilization of β-catenin and the
subsequent suppression of cyclin D1 and c-myc expression. Methyl
1-[N6-(3-iodobenzyl)-adenin-9-yl]-β-Dribofuronamid (IB-MECA)
treatment also induced down-modulation of the expression of
NF-kB, known to regulate the transcription of cyclin D1 and c-Myc
[116,117]. IB-MECA and 2-Chloro-N6-3-iodobenzyladenosine-5′-N-
methyluronamide (Cl-IB-MECA) were tested both in vitro and in vivo
at low concentrations and dosages, respectively. Remarkably, at this
low concentration range these agonists induced a differential effect on
tumor and normal cell proliferation. Inhibition of the growth of tumor
cells, including rat Nb2–11C and mouse Yac-1 lymphoma, K-562
leukemia, B16-F10 melanoma, MCA sarcoma, human LN-Cap and PC3
prostate carcinoma, MIA-PaCa pancreatic carcinoma and HCT-116
colon carcinoma, was found [101,117–123]. This effect was abolished
by A3AR antagonists [124], demonstrating that the response was A3AR
mediated. The A3AR reduces the ability of prostate cancer cells to
migrate in vitro and metastasize in vivo. In particular, it has been
reported that activation of the A3AR in prostate cancer cells reduced
protein kinase A-mediated stimulation of ERK1/2, leading to lower
NADPH oxidase activity and cancer cell invasiveness [104]. In a
different study, the biological functions of adenosine in metallopro-
teinase-9 (MMP-9) regulation in U87MG human glioblastoma cells
were investigated. In this case, it was revealed that A3AR stimulation
induced an increase of MMP-9 levels in U87MG cells by phosphory-
lation of ERK1/2, c-Jun N-terminal kinase/stress-activated protein
kinase (pJNK/SAPK), PKB/Akt and ﬁnally activator protein 1 (AP-1).
This effect was responsible for an increase of glioblastoma cells
invasion [42].
In a series of other studies it has been found that inhibition of cell
proliferation, or induction of apoptosis with the A3 agonist, were
obtainedonlybymicromolardoses of theA3 agonists [113,114,125,126].
In melanoma cells Cl-IB-MECA inhibited cell proliferation in an A3AR-
dependent manner [113]. IB-MECA produced cell growth inhibition in
both ERα-positive cells and in ERα-negative human breast carcinoma
cells. In both cell types, the introduction of an A3AR antagonist blocked
the effect of this A3AR agonist [125,127]. Addition of the A3AR agonist
2-chloro-N6-(3-iodobenzyl)-4′-thioadenosine-5′-N-methyluronamide(thio-Cl-IB-MECA) to HL-60 human leukemia cell cultures resulted in
apoptosis [126,128]. Interestingly, an additional compound that inhibits
the growth of tumor cells via A3AR is 3′-deoxyadenosine (cordycepin),
an active ingredient of Cordyceps sinensis, a parasitic fungus used in
traditional Chinesemedicine [114]. Thismolecule, at μMconcentrations,
induced a remarkable inhibitory effect on the growth of murine
melanoma and of Lewis lung carcinoma tumor cells. This inhibitory
effect was abolished by the A3AR antagonist 3-ethyl-5-benzyl-2-
methyl-4-phenylethynyl-6-phenyl-1,4-(±)-dihydropyridine-3,5-
dicarboxylate (MRS1191) [114].
Indeed, agonists to the A3AR exert a differential effect on normal and
tumor cells. In normal cells, the agonists induce the production of
growth factors via induction of the NF-κB signaling pathway. In vitro
studies were also conﬁrmed by in vivo experiments, which revealed an
increase in white blood cell numbers, when adenosine was adminis-
tered before chemotherapy [101,117,119,120,129–131]. The molecular
mechanism at the basis of granulocyte-colony stimulating factor (G-
CSF) production included the upregulation of PI3K, PKB/Akt and NF-kB.
In addition, it has been observed that Cl-IB-MECA potentiates the
activity of NK cells in naïve and tumor bearing mice through the
inductionof IL-12production. This effectwasdependent on inhibitionof
cAMP levels and PKA expression. IL-12 is a potent stimulant of NK cells
and is a cytotoxic factor that exerts a potent antitumor effect in vivo
[132]. Therefore, A3AR activation enhances NK cell activity and probably
NK cell-mediated destruction of tumor cells [133].
However, the involvement of A3AR in the inhibition of cancer
development has been questioned by other authors. For example, IB-
MECA and Cl-IB-MECA at μM concentrations inhibit the growth of
various tumor cell lines (includingNPApapillary thyroid carcinoma, HL-
60 leukemia cells and U-937 lymphoma cells) in an A3AR-independent
mechanism [107,134]. This inhibitory effect was characterized by
apoptosis and was not abolished by antagonism or knockdown of the
A3AR. Based on these results, it was concluded that IB-MECA or Cl-IB-
MECA at high concentrations can induce tumor cell death through
receptor-independent mechanisms, perhaps via active transport into
the cells through the nucleoside transporters [107,134]. Furthermore, it
has been previously reported that IB-MECA, at micromolar doses in
breast cancer cells, inhibits cell proliferation through interaction with
receptors different from the adenosine subtypes such as ER α [135].
Indeed at micromolar doses Cl-IB-MECA loses its selectivity for A3ARs
and the complicating presence of interaction with other adenosine
subtypes might be involved in the ﬁnal response. Furthermore, the
difference between the effects induced by low and high doses of Cl-IB-
MECA could be attributed to the receptor desensitization of A3ARs [136].
Conversely, it has been demonstrated that A3AR in retinal ganglion cells
was obligatory for life [137] and it has been observed in colon cancer
Fig. 5. Role of A3AR in cancer development. Schematic representation of the principal pathways activated by A3AR in the modulation of pro- and anti-tumoral effects.
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MECA increased cell proliferation through the activation of A3 subtype
and involvement of ERK 1/2 [41].
The involvement of the A3ARs in hypoxic conditions, an in vitro
model reproducing the microenvironment of solid tumors in vivo, has
also been studied. Hypoxia that is typical of solid tumors [138], creates
conditions that, on the one hand, are conducive to the accumulation of
extracellular adenosine and, on the other hand, stabilize hypoxia-
inducible factors, such as HIF-1α [12,56,139–143]. HIF-1, the most
important factor involved in the cellular response to hypoxia, is
upregulated across a broad range of cancer types and is involved in
key aspects of tumor biology such as angiogenesis, invasion, and altered
energy metabolism [144]. HIF-1 is a heterodimer composed of an
inducibly-expressed HIF-1α subunit and a constitutively-expressed
HIF-1β subunit [145].
The unique feature of HIF-1 is the regulation of HIF-1α expression. It
increases as the cellular O2 concentration is decreased [139,141]. During
normoxia, HIF-1α is rapidly degraded by the ubiquitin proteasome
system, whereas exposure to hypoxic conditions prevents its degrada-
tion [141]. A growing body of evidence indicates that HIF-1 contributes
to tumor progression andmetastasis [146,147]. Interestingly, it has been
demonstrated that A3ARs are also over expressed in cancer tissues in
comparison to normal mucosa [105]. Furthermore, attention has been
paid to responses to chronic hypoxia that involve adenosine-induced
changes in the transcription regulator HIF-1 expression. In particular,
the correlation between AR stimulation and HIF-1α expression
modulation in hypoxia has been investigated. Adenosine increases
HIF-1α protein expression in response to hypoxia in humanmelanoma,
glioblastomaand colon cancer cells [103,148,149]. These results indicate
that the cell surface A3AR transduces extracellular hypoxic signals into
the cell interior. Increased HIF-1α protein synthesis through the
activation of the Akt orMAPK pathways is a common theme accounting
for the upregulation. To evaluate how A3AR accumulates HIF-1α in
hypoxia, the signalingpathwaygenerated byA3AR stimulation has been
investigated and it was found thatMAPK activity is required for the HIF-
1α expression increase induced by A3AR activation. Furthermore, as
HIF-1αplays a key role in inducingangiogenesis, the role of adenosine in
mediating the production of VEGF in tumor cells has been studied.
Activation of the A3AR in glioblastoma and colon cancer cells stimulates
VEGF expression [103,149], whereas this receptor subtype promotes
VEGF downregulation in pheochromocytoma cells (PC12) [150]. It hasbeen proposed that the effect of VEGF on new capillary formation is
facilitated by the concomitant stimulation of A2B and A3ARs that induce
the expression of VEGF and angiopoietin-2, respectively [88]. Indeed,
the activation of A3ARs results in increased expression of angiopoietin-2
in mast and melanoma cells [88,148]. Although adenosine may
contribute rather little to the increase in VEGF induced by hypoxia, it
may contribute as much as 50% to angiogenesis [151]. This could mean
that adenosine also acts independently of VEGF, something that is not
unlikely, given the involvement of multiple cell types and multiple
angiogenetic factors. Recent studies indicate that pharmacological
inhibition of HIF-1α and particularly of HIF-regulated genes, that are
important for cancer cell survival, may be more advantageous than
therapeutic approaches based on HIF-gene inactivation. In this regard,
A3AR antagonists are able to block HIF-1α, angiopoietin-2 and VEGF
protein expression accumulation in hypoxia, indicating a new approach
for the treatment of cancer, based on the cooperation between hypoxic
and adenosine signals. It is interesting to note that etoposide and
doxorubicin affect VEGF and HIF-1 expression in human melanoma
cancer cells. In particular, in blocking A3ARs it is possible to further
decrease VEGF secretion in melanoma cells, HIF-1-dependent, treated
with etoposide and doxorubicin. This understanding may present the
possibility of using adenosine antagonists to improve the ability of
chemotherapeutic drugs to block angiogenesis [96].
The pro- and anti-tumoral effects induced by A3AR activation are
summarized in Fig. 5.
The scientiﬁc work performed in the ﬁeld of cancer and ARs has led
to the development of in vivo studies only for the A3AR. Below, the
principal ﬁndings obtained in animal studies will be summarized.
In all experimental models, the A3AR agonists were administered
orally due to their stability and bioavailability proﬁle. The studies
included syngeneic, xenograft, orthotopic and metastatic experimental
animal models utilizing IB-MECA and Cl-IB-MECA as the therapeutic
agents in melanoma, colon, prostate and hepatocellular carcinomas.
Oral administration of 10–100 μg kg−1 IB-MECA and Cl-IB-MECA once
or twice daily inhibited the growth of primary B16-F10 murine
melanoma tumors in syngeneic models [124]. Moreover, in an artiﬁcial
metastatic model, IB-MECA inhibited the development of B16-F10
murine melanoma lung metastases [118–120]. The speciﬁcity of the
response was demonstrated by the administration of an A3AR
antagonist that reversed the effect of the agonist [124]. Furthermore,
IB-MECA or Cl-IB-MECA in combination with the chemotherapeutic
Table 1
The main role of adenosine receptors in cancer.
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development of B16-F10melanoma lungmetastatic foci [119,120]. Oral
administration of 10–100 μg kg−1 IB-MECA once or twice daily
inhibited the growthof primary CT-26 colon tumors [123]. Furthermore,
in xenograft models, IB-MECA inhibited the development of HCT-116
human colon carcinoma in nude mice [123]. In these studies, thecombined treatment of IB-MECA and 5-ﬂuorouracil resulted in an
enhanced antitumor effect. IB-MECA was also efﬁcacious in inhibiting
liver metastases of CT-26 colon carcinoma cells inoculated in the spleen
[116,120,123,152]. IB-MECA inhibited the development of PC3 human
prostate carcinoma in nude mice. Additionally, IB-MECA increased the
cytotoxic index of Taxol in PC3 prostate carcinoma-bearing mice
1409S. Gessi et al. / Biochimica et Biophysica Acta 1808 (2011) 1400–1412[117,120]. Finally, Cl-IB-MECA treatment dose-dependently inhibited
hepatocellular tumor growth [109].
8. Conclusions
The study of adenosine and its ARs in cancer is a rapidly growing and
intense area of research in drug discovery [153,154]. Adenosine, the
endogenous ligand of the four AR subtypes, may activate all of these
receptors in cancer due to its increased concentration in the tumor
microenvironment. Its role in producing pro- and anticancer effects via
each of its receptor subtypes is reported in this review (Figs. 1–3, 5). In
particular, similarities and differences between receptors are easily
appreciated in Table 1. It appears that all the ARs are possible targets for
the development of novel approaches to the treatment of cancer. The
antitumorigenic role of A1AR in cancer was mainly studied in A1AR KO
mice, demonstrating that activation of the A1AR on microglia inhibits
thegrowthof glioblastomas. As forA2AAR, it has been suggested that this
subtype blocks antitumor immunity. In the tumor environment of
hypoxia and high adenosine levels, activation of A2AARs leads to
immunosuppressive effects, which decreases antitumor immunity and
thus encourages tumor growth. Due to this behavior, it was suggested
that the addition of A2AAR antagonists to cancer immunotherapeutic
protocolsmay enhance tumor immunotherapy. Interestingly, the safety
of such compounds has already been shown in trials employing A2AAR
antagonists for the treatment of Parkinson's disease. The role of the
A2BAR in cancer is not well deﬁned. On the one hand, activation of
A2BARs leads to the release of angiogenic factors that promote tumor
growth. On the other hand, the activation of A2BARs may exert an
inhibitory signal on tumor cell proliferation. From these data it is not
possible to understand whether agonists or antagonists will produce
anticancer effects. Finally, with regard to the A3ARs, due to their high
expression in tumor cells, it has been suggested that this receptor
subtype is an attractive target to combat cancer (Fig. 4). A3AR activation
with synthetic agonists induces inhibition of cell proliferation and
apoptosis toward different cancer cells both in vitro and in vivo
experimentalmodels. Pre-clinical and Phase I/II studies show that these
agonists are safe and well tolerated in humans and thus may be
considered therapeutic agents for certain tumors such as HCC, where a
signiﬁcant apoptotic effect was demonstrated. However, by blocking
hypoxia-induced increases of HIF-1α, angiogenesis and cell invasion in
the tumor microenvironment, A3AR antagonists may represent a
successful approach for the treatment of cancer.
At present new therapeutic candidates in the ﬁght against cancer
are near to being available from the “adenosinergic system”.
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